The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial

Author(s):
Huijbers, A.; Pelt, G.W. van (0000-0003-1449-7348); Kerr, R.S.; Johnstone, E.C.; Tollenaar, R.A.E.M. (0000-0002-6831-6082); Kerr, D.J.; Mesker, W.E. (0000-0001-5533-4778)
Published
2018
Publication type
Article / Letter to editor
personalized therapyprognosistumor microenvironmenttumor-stroma ratiovascular invasion
Date issued
2018-04-01
Language
English
Is part of
Journal of Surgical Oncology (2018), Vol. 117, no. 5, p. 1043-1048
hdl
1887/95471
doi
10.1002/jso.24998